Join to View Full Profile
1515 Holcombe BlvdHouston, TX 77030
Phone+1 713-792-6161
Dr. Symmans is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
NYU Grossman School of MedicineResidency, Immunopathology, 1993 - 1995
University of Texas M D Anderson Cancer CenterFellowship, Blood Banking/Transfusion Medicine, 1992 - 1993
New York Presbyterian Hospital (Columbia Campus)Residency, Pathology-Anatomic and Clinical, 1988 - 1992
University of Auckland Faculty of Medicine and Health SciencesClass of 1986
Certifications & Licensure
TX State Medical License 2000 - 2027
NY State Medical License 1996 - 2003
PA State Medical License 1992 - 1996
American Board of Pathology Anatomic Pathology- American Board of Pathology Cytopathology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
Publications & Presentations
PubMed
- Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a r...Nadia Harbeck, Shanu Modi, Lajos Pusztai, Shinji Ohno, Jiong Wu
Annals of Oncology. 2025-10-18 - ADAMs contribute to triple negative breast cancer via mTORC1 pathway: targeting ADAM-mTOR axis improves efficacy.Shuying Liu, Huiqin Chen, Mihai Gagea, Lorenzo Federico, Fan Zhang
Cancer Letters. 2025-08-28 - Impact of adding palbociclib on treatment adherence to ongoing adjuvant endocrine treatment in the global randomized PALLAS randomized trial in patients with early bre...Eileen Shinn, David Zahrieh, Angela DeMichele, Nick Zdenkowski, Julie Lemieux
Breast Cancer Research and Treatment. 2025-06-01
Press Mentions
Residual Cancer Burden Predicts Outcomes for All Breast Cancer TypesFebruary 25th, 2020
Grant Support
- Evaluation of the Sensitivity to Endocrine Therapy (SET ER/PR) Assay to predict benefit from extended duration of adjuvant endocrine therapy in the NSABP B-42 trialUNIVERSITY OF TX MD ANDERSON CAN CTR2023–2025
Committees
- Member, Expert Panel, American Society of Clinical Oncology (ASCO) 2015 - Present
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
